\u3053\u3061\u3089<\/a> \uff1e<\/p>","protected":false},"excerpt":{"rendered":"PRISM Biolab\u306f\u3001\u3053\u306e\u305f\u3073\u3001\u5f53\u793e\u304c\u5927\u539f\u85ac\u54c1\u5de5\u696d\u682a\u5f0f\u4f1a\u793e\u306b\u30e9\u30a4\u30bb\u30f3\u30b9\u3057\u305fPRI-724\/OP-724\uff08\u4e00\u822c\u540d\u300c\u30db\u30b9\u30bb\u30f3\u30d3\u30d3\u30f3\u30c8\u300d\uff09\u306b\u95a2\u3057\u3066\u3001\u85ac\u7269\u9593\u76f8\u4e92\u4f5c\u7528\u306b\u95a2\u3059\u308b\u7b2cI\u76f8\u81e8\u5e8a\u8a66\u9a13\u304c\u958b\u59cb\u3055\u308c\u305f\u3053\u3068\u3092\u304a\u77e5\u3089\u305b\u3044\u305f\u3057\u307e\u3059\u3002<\/p>","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","tags":[],"news-category":[8],"class_list":["post-2302","news","type-news","status-publish","hentry","news-category-news","post"],"yoast_head":"\n
PRISM BioLab Announces Initiation of Patient Enrollment in a Phase I Drug-Drug Interaction Study of PRI-724 by Ohara Pharmaceutical - PRISM BioLab<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/prismbiolab.com\/ja\/news\/prism-biolab-announces-initiation-of-patient-enrollment-in-a-phase-i-drug-drug-interaction-study-of-pri-724-by-ohara-pharmaceutical\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PRISM BioLab Announces Initiation of Patient Enrollment in a Phase I Drug-Drug Interaction Study of PRI-724 by Ohara Pharmaceutical - PRISM BioLab\" \/>\n<meta property=\"og:description\" content=\"PRISM BioLab is pleased to announce that a Phase I clinical study on drug-drug interactions of PRI-724\/OP-724 (generic name: foscelbinib), which has been licensed to Ohara Pharmaceutical Co., Ltd., has been initiated. For more details, please click here (Japanese language PDF).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/prismbiolab.com\/ja\/news\/prism-biolab-announces-initiation-of-patient-enrollment-in-a-phase-i-drug-drug-interaction-study-of-pri-724-by-ohara-pharmaceutical\/\" \/>\n<meta property=\"og:site_name\" content=\"PRISM BioLab\" \/>\n<meta property=\"og:image\" content=\"https:\/\/prismbiolab.com\/wp-content\/uploads\/2024\/07\/career-collage.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1122\" \/>\n\t<meta property=\"og:image:height\" content=\"1097\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/news\\\/prism-biolab-announces-initiation-of-patient-enrollment-in-a-phase-i-drug-drug-interaction-study-of-pri-724-by-ohara-pharmaceutical\\\/\",\"url\":\"https:\\\/\\\/prismbiolab.com\\\/news\\\/prism-biolab-announces-initiation-of-patient-enrollment-in-a-phase-i-drug-drug-interaction-study-of-pri-724-by-ohara-pharmaceutical\\\/\",\"name\":\"PRISM BioLab Announces Initiation of Patient Enrollment in a Phase I Drug-Drug Interaction Study of PRI-724 by Ohara Pharmaceutical - PRISM BioLab\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/#website\"},\"datePublished\":\"2025-11-05T19:11:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/news\\\/prism-biolab-announces-initiation-of-patient-enrollment-in-a-phase-i-drug-drug-interaction-study-of-pri-724-by-ohara-pharmaceutical\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/prismbiolab.com\\\/news\\\/prism-biolab-announces-initiation-of-patient-enrollment-in-a-phase-i-drug-drug-interaction-study-of-pri-724-by-ohara-pharmaceutical\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/news\\\/prism-biolab-announces-initiation-of-patient-enrollment-in-a-phase-i-drug-drug-interaction-study-of-pri-724-by-ohara-pharmaceutical\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/prismbiolab.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/prismbiolab.com\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"PRISM BioLab Announces Initiation of Patient Enrollment in a Phase I Drug-Drug Interaction Study of PRI-724 by Ohara Pharmaceutical\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/#website\",\"url\":\"https:\\\/\\\/prismbiolab.com\\\/\",\"name\":\"PRISM BioLab\",\"description\":\"PRISM BioLab MIMICS natural peptides leading to cures of the greatest health challenges\",\"publisher\":{\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/prismbiolab.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/#organization\",\"name\":\"PRISM BioLab\",\"url\":\"https:\\\/\\\/prismbiolab.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/prismbiolab.com\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/prism_logo_b.jpg\",\"contentUrl\":\"https:\\\/\\\/prismbiolab.com\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/prism_logo_b.jpg\",\"width\":300,\"height\":367,\"caption\":\"PRISM BioLab\"},\"image\":{\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PRISM BioLab\u3001\u5927\u539f\u85ac\u54c1\u306b\u3088\u308bPRI-724\u306e\u85ac\u7269\u9593\u76f8\u4e92\u4f5c\u7528\u306b\u95a2\u3059\u308b\u7b2cI\u76f8\u81e8\u5e8a\u8a66\u9a13\u306e\u75c7\u4f8b\u767b\u9332\u958b\u59cb\u3092\u767a\u8868 - PRISM BioLab","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/prismbiolab.com\/ja\/news\/prism-biolab-announces-initiation-of-patient-enrollment-in-a-phase-i-drug-drug-interaction-study-of-pri-724-by-ohara-pharmaceutical\/","og_locale":"ja_JP","og_type":"article","og_title":"PRISM BioLab Announces Initiation of Patient Enrollment in a Phase I Drug-Drug Interaction Study of PRI-724 by Ohara Pharmaceutical - PRISM BioLab","og_description":"PRISM BioLab is pleased to announce that a Phase I clinical study on drug-drug interactions of PRI-724\/OP-724 (generic name: foscelbinib), which has been licensed to Ohara Pharmaceutical Co., Ltd., has been initiated. For more details, please click here (Japanese language PDF).","og_url":"https:\/\/prismbiolab.com\/ja\/news\/prism-biolab-announces-initiation-of-patient-enrollment-in-a-phase-i-drug-drug-interaction-study-of-pri-724-by-ohara-pharmaceutical\/","og_site_name":"PRISM BioLab","og_image":[{"width":1122,"height":1097,"url":"https:\/\/prismbiolab.com\/wp-content\/uploads\/2024\/07\/career-collage.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/prismbiolab.com\/news\/prism-biolab-announces-initiation-of-patient-enrollment-in-a-phase-i-drug-drug-interaction-study-of-pri-724-by-ohara-pharmaceutical\/","url":"https:\/\/prismbiolab.com\/news\/prism-biolab-announces-initiation-of-patient-enrollment-in-a-phase-i-drug-drug-interaction-study-of-pri-724-by-ohara-pharmaceutical\/","name":"PRISM BioLab\u3001\u5927\u539f\u85ac\u54c1\u306b\u3088\u308bPRI-724\u306e\u85ac\u7269\u9593\u76f8\u4e92\u4f5c\u7528\u306b\u95a2\u3059\u308b\u7b2cI\u76f8\u81e8\u5e8a\u8a66\u9a13\u306e\u75c7\u4f8b\u767b\u9332\u958b\u59cb\u3092\u767a\u8868 - PRISM BioLab","isPartOf":{"@id":"https:\/\/prismbiolab.com\/#website"},"datePublished":"2025-11-05T19:11:52+00:00","breadcrumb":{"@id":"https:\/\/prismbiolab.com\/news\/prism-biolab-announces-initiation-of-patient-enrollment-in-a-phase-i-drug-drug-interaction-study-of-pri-724-by-ohara-pharmaceutical\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/prismbiolab.com\/news\/prism-biolab-announces-initiation-of-patient-enrollment-in-a-phase-i-drug-drug-interaction-study-of-pri-724-by-ohara-pharmaceutical\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/prismbiolab.com\/news\/prism-biolab-announces-initiation-of-patient-enrollment-in-a-phase-i-drug-drug-interaction-study-of-pri-724-by-ohara-pharmaceutical\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/prismbiolab.com\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/prismbiolab.com\/news\/"},{"@type":"ListItem","position":3,"name":"PRISM BioLab Announces Initiation of Patient Enrollment in a Phase I Drug-Drug Interaction Study of PRI-724 by Ohara Pharmaceutical"}]},{"@type":"WebSite","@id":"https:\/\/prismbiolab.com\/#website","url":"https:\/\/prismbiolab.com\/","name":"PRISM BioLab","description":"PRISM BioLab MIMICS natural peptides leading to cures of the greatest health challenges","publisher":{"@id":"https:\/\/prismbiolab.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/prismbiolab.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/prismbiolab.com\/#organization","name":"PRISM BioLab","url":"https:\/\/prismbiolab.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/prismbiolab.com\/#\/schema\/logo\/image\/","url":"https:\/\/prismbiolab.com\/wp-content\/uploads\/2021\/09\/prism_logo_b.jpg","contentUrl":"https:\/\/prismbiolab.com\/wp-content\/uploads\/2021\/09\/prism_logo_b.jpg","width":300,"height":367,"caption":"PRISM BioLab"},"image":{"@id":"https:\/\/prismbiolab.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/news\/2302","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/types\/news"}],"author":[{"embeddable":true,"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/comments?post=2302"}],"version-history":[{"count":1,"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/news\/2302\/revisions"}],"predecessor-version":[{"id":2304,"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/news\/2302\/revisions\/2304"}],"wp:attachment":[{"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/media?parent=2302"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/tags?post=2302"},{"taxonomy":"news-category","embeddable":true,"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/news-category?post=2302"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}